NASDAQ:EWTX

Edgewise Therapeutics Competitors

$29.24
-0.06 (-0.20 %)
(As of 05/7/2021 12:00 AM ET)
Add
Compare
Today's Range
$28.02
$30.00
50-Day Range N/A
52-Week Range
$23.56
$40.49
Volume98,802 shs
Average Volume194,910 shs
Market Capitalization$1.39 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Edgewise Therapeutics (NASDAQ:EWTX) Vs. ABCM, RXRX, SANA, SEER, NUVB, and IBRX

Should you be buying EWTX stock or one of its competitors? Companies in the industry of "biotechnology" are considered alternatives and competitors to Edgewise Therapeutics, including Abcam (ABCM), Recursion Pharmaceuticals (RXRX), Sana Biotechnology (SANA), Seer (SEER), Nuvation Bio (NUVB), and ImmunityBio (IBRX).

Edgewise Therapeutics (NASDAQ:EWTX) and Abcam (NASDAQ:ABCM) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, valuation, profitability, earnings, dividends, analyst recommendations and institutional ownership.

Analyst Ratings

This is a breakdown of current recommendations for Edgewise Therapeutics and Abcam, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Edgewise Therapeutics01302.75
Abcam04302.43

Edgewise Therapeutics presently has a consensus target price of $34.25, indicating a potential upside of 17.13%. Abcam has a consensus target price of $22.00, indicating a potential upside of 3.48%. Given Edgewise Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Edgewise Therapeutics is more favorable than Abcam.

Profitability

This table compares Edgewise Therapeutics and Abcam's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Edgewise TherapeuticsN/AN/AN/A
AbcamN/AN/AN/A

Earnings & Valuation

This table compares Edgewise Therapeutics and Abcam's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Edgewise TherapeuticsN/AN/AN/AN/AN/A
AbcamN/AN/AN/AN/AN/A

Summary

Edgewise Therapeutics beats Abcam on 2 of the 2 factors compared between the two stocks.

Edgewise Therapeutics (NASDAQ:EWTX) and Recursion Pharmaceuticals (NASDAQ:RXRX) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, valuation, profitability, earnings, dividends, analyst recommendations and institutional ownership.

Analyst Ratings

This is a breakdown of current recommendations for Edgewise Therapeutics and Recursion Pharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Edgewise Therapeutics01302.75
Recursion Pharmaceuticals0000N/A

Edgewise Therapeutics presently has a consensus target price of $34.25, indicating a potential upside of 17.13%. Given Edgewise Therapeutics' higher probable upside, analysts clearly believe Edgewise Therapeutics is more favorable than Recursion Pharmaceuticals.

Profitability

This table compares Edgewise Therapeutics and Recursion Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Edgewise TherapeuticsN/AN/AN/A
Recursion PharmaceuticalsN/AN/AN/A

Earnings & Valuation

This table compares Edgewise Therapeutics and Recursion Pharmaceuticals' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Edgewise TherapeuticsN/AN/AN/AN/AN/A
Recursion PharmaceuticalsN/AN/AN/AN/AN/A

Summary

Edgewise Therapeutics beats Recursion Pharmaceuticals on 2 of the 2 factors compared between the two stocks.

Edgewise Therapeutics (NASDAQ:EWTX) and Sana Biotechnology (NASDAQ:SANA) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, valuation, profitability, earnings, dividends, analyst recommendations and institutional ownership.

Analyst Ratings

This is a breakdown of current recommendations for Edgewise Therapeutics and Sana Biotechnology, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Edgewise Therapeutics01302.75
Sana Biotechnology02202.50

Edgewise Therapeutics presently has a consensus target price of $34.25, indicating a potential upside of 17.13%. Sana Biotechnology has a consensus target price of $40.00, indicating a potential upside of 120.14%. Given Sana Biotechnology's higher probable upside, analysts clearly believe Sana Biotechnology is more favorable than Edgewise Therapeutics.

Profitability

This table compares Edgewise Therapeutics and Sana Biotechnology's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Edgewise TherapeuticsN/AN/AN/A
Sana BiotechnologyN/AN/AN/A

Earnings & Valuation

This table compares Edgewise Therapeutics and Sana Biotechnology's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Edgewise TherapeuticsN/AN/AN/AN/AN/A
Sana BiotechnologyN/AN/AN/AN/AN/A

Summary

Edgewise Therapeutics beats Sana Biotechnology on 2 of the 3 factors compared between the two stocks.

Edgewise Therapeutics (NASDAQ:EWTX) and Seer (NASDAQ:SEER) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, valuation, profitability, earnings, dividends, analyst recommendations and institutional ownership.

Analyst Ratings

This is a breakdown of current recommendations for Edgewise Therapeutics and Seer, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Edgewise Therapeutics01302.75
Seer02202.50

Edgewise Therapeutics presently has a consensus target price of $34.25, indicating a potential upside of 17.13%. Seer has a consensus target price of $68.00, indicating a potential upside of 78.57%. Given Seer's higher probable upside, analysts clearly believe Seer is more favorable than Edgewise Therapeutics.

Profitability

This table compares Edgewise Therapeutics and Seer's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Edgewise TherapeuticsN/AN/AN/A
SeerN/AN/AN/A

Earnings & Valuation

This table compares Edgewise Therapeutics and Seer's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Edgewise TherapeuticsN/AN/AN/AN/AN/A
SeerN/AN/AN/AN/AN/A

Summary

Edgewise Therapeutics beats Seer on 2 of the 3 factors compared between the two stocks.

Edgewise Therapeutics (NASDAQ:EWTX) and Nuvation Bio (NYSE:NUVB) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, valuation, profitability, earnings, dividends, analyst recommendations and institutional ownership.

Analyst Ratings

This is a breakdown of current recommendations for Edgewise Therapeutics and Nuvation Bio, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Edgewise Therapeutics01302.75
Nuvation Bio00603.00

Edgewise Therapeutics presently has a consensus target price of $34.25, indicating a potential upside of 17.13%. Nuvation Bio has a consensus target price of $17.40, indicating a potential upside of 74.00%. Given Nuvation Bio's stronger consensus rating and higher probable upside, analysts clearly believe Nuvation Bio is more favorable than Edgewise Therapeutics.

Profitability

This table compares Edgewise Therapeutics and Nuvation Bio's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Edgewise TherapeuticsN/AN/AN/A
Nuvation BioN/AN/AN/A

Earnings & Valuation

This table compares Edgewise Therapeutics and Nuvation Bio's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Edgewise TherapeuticsN/AN/AN/AN/AN/A
Nuvation BioN/AN/AN/AN/AN/A

Summary

Nuvation Bio beats Edgewise Therapeutics on 3 of the 3 factors compared between the two stocks.

Edgewise Therapeutics (NASDAQ:EWTX) and ImmunityBio (NASDAQ:IBRX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, earnings, analyst recommendations, dividends, institutional ownership, valuation and risk.

Analyst Recommendations

This is a breakdown of current ratings for Edgewise Therapeutics and ImmunityBio, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Edgewise Therapeutics01302.75
ImmunityBio00103.00

Edgewise Therapeutics presently has a consensus target price of $34.25, indicating a potential upside of 17.13%. ImmunityBio has a consensus target price of $25.00, indicating a potential upside of 49.34%. Given ImmunityBio's stronger consensus rating and higher probable upside, analysts plainly believe ImmunityBio is more favorable than Edgewise Therapeutics.

Profitability

This table compares Edgewise Therapeutics and ImmunityBio's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Edgewise TherapeuticsN/AN/AN/A
ImmunityBioN/AN/AN/A

Valuation & Earnings

This table compares Edgewise Therapeutics and ImmunityBio's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Edgewise TherapeuticsN/AN/AN/AN/AN/A
ImmunityBioN/AN/AN/AN/AN/A

Summary

ImmunityBio beats Edgewise Therapeutics on 2 of the 3 factors compared between the two stocks.


Edgewise Therapeutics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Abcam logo
ABCM
Abcam
1.1$21.26-2.4%$4.82 billionN/A0.00Gap Down
RXRX
Recursion Pharmaceuticals
0.0$27.73-1.0%$4.50 billionN/A0.00Gap Up
Sana Biotechnology logo
SANA
Sana Biotechnology
1.2$18.17-8.4%$3.41 billionN/A0.00Gap Down
SEER
Seer
1.2$38.08-5.6%$2.32 billionN/A0.00Upcoming Earnings
Gap Up
Nuvation Bio logo
NUVB
Nuvation Bio
2.2$10.00-0.0%$2.18 billionN/A0.00
IBRX
ImmunityBio
1.7$16.74-4.4%$1.83 billionN/A0.00Upcoming Earnings
Gap Down
Immunocore logo
IMCR
Immunocore
1.3$40.31-1.6%$1.74 billionN/A0.00
BioAtla logo
BCAB
BioAtla
1.7$46.81-2.8%$1.58 billionN/A0.00Analyst Report
Gap Down
Cullinan Oncology logo
CGEM
Cullinan Oncology
1.4$29.86-2.9%$1.30 billionN/A0.00Gap Down
Nurix Therapeutics logo
NRIX
Nurix Therapeutics
2.0$26.94-1.6%$1.19 billionN/A0.00Analyst Report
KNTE
Kinnate Biopharma
1.7$24.68-3.6%$1.07 billionN/A0.00Analyst Revision
News Coverage
Gap Down
Silverback Therapeutics logo
SBTX
Silverback Therapeutics
1.7$28.16-0.5%$982.87 millionN/A0.00
STEM
Stem
0.0$20.04-3.9%$960.88 millionN/A0.00News Coverage
Gap Up
Vor Biopharma logo
VOR
Vor Biopharma
1.9$24.53-3.6%$910.75 millionN/A0.00Analyst Downgrade
News Coverage
CNTB
Connect Biopharma
1.7$15.53-3.7%$893.04 millionN/A0.00Gap Up
FDMT
4D Molecular Therapeutics
1.3$32.80-2.4%$875.56 millionN/A0.00Gap Up
Pharming Group logo
PHAR
Pharming Group
0.0$13.20-4.5%$846.50 millionN/A0.00
Bolt Biotherapeutics logo
BOLT
Bolt Biotherapeutics
1.6$22.85-2.3%$830.10 millionN/A0.00Gap Up
iTeos Therapeutics logo
ITOS
iTeos Therapeutics
1.9$23.10-3.8%$810.79 millionN/A0.00Upcoming Earnings
Analyst Report
Gap Up
Gracell Biotechnologies logo
GRCL
Gracell Biotechnologies
1.4$11.50-0.0%$772.95 millionN/A0.00Analyst Upgrade
Pharvaris B.V. logo
PHVS
Pharvaris B.V.
1.5$22.63-7.6%$720.54 millionN/A0.00News Coverage
Gap Up
FNCH
Finch Therapeutics Group
2.0$12.66-2.1%$596.86 millionN/A0.00Gap Up
ACHL
Achilles Therapeutics plc American Depositary Shares
1.6$14.17-0.8%$575.61 millionN/A0.00Quiet Period Expiration
Gap Up
Inventiva logo
IVA
Inventiva
1.4$14.40-0.1%$556.27 millionN/A0.00Analyst Report
Gemini Therapeutics logo
GMTX
Gemini Therapeutics
1.7$11.98-0.2%$515.13 millionN/A0.00
BMEA
Biomea Fusion
0.0$16.94-0.8%$487.33 millionN/A0.00
MIGI
Mawson Infrastructure Group
0.0$1.05-5.7%$481.46 millionN/A0.00Gap Down
RAIN
Rain Therapeutics
1.3$18.39-9.4%$477.57 millionN/A0.00Gap Down
VECT
VectivBio
1.5$13.50-1.9%$459.20 millionN/A0.00Analyst Report
Analyst Revision
NexImmune logo
NEXI
NexImmune
2.0$19.59-1.1%$445.83 millionN/A0.00Analyst Revision
News Coverage
Angion Biomedica logo
ANGN
Angion Biomedica
1.6$14.24-0.6%$419.85 millionN/A0.00
Landos Biopharma logo
LABP
Landos Biopharma
1.8$10.46-3.5%$419.63 millionN/A0.00News Coverage
Gap Up
SGTX
Sigilon Therapeutics
1.4$13.30-1.8%$419.34 millionN/A0.00News Coverage
Terns Pharmaceuticals logo
TERN
Terns Pharmaceuticals
2.0$16.62-3.4%$417.58 millionN/A0.00News Coverage
Gap Down
Sensei Biotherapeutics logo
SNSE
Sensei Biotherapeutics
2.0$11.86-0.5%$362.77 millionN/A0.00News Coverage
Gap Down
RPHM
Reneo Pharmaceuticals
2.0$14.93-0.6%$361.47 millionN/A0.00Analyst Report
Analyst Revision
News Coverage
PRTG
Portage Biotech
0.0$27.97-1.1%$337.96 millionN/A0.00
Kaleido Biosciences logo
KLDO
Kaleido Biosciences
1.8$7.46-2.3%$317.19 millionN/A-2.95Earnings Announcement
IMPL
Impel NeuroPharma
0.3$15.03-0.3%$291.81 millionN/A0.00
Unity Biotechnology logo
UBX
Unity Biotechnology
1.1$4.63-2.8%$253.67 millionN/A-2.46Analyst Revision
News Coverage
Gap Down
VINC
Vincerx Pharma
1.0$15.75-6.8%$220.25 millionN/A0.00Gap Down
Decibel Therapeutics logo
DBTX
Decibel Therapeutics
2.2$7.90-6.1%$196.73 millionN/A0.00Gap Down
LBPH
Longboard Pharmaceuticals
1.9$9.97-6.9%$168.66 millionN/A0.00Analyst Revision
Gap Down
Annovis Bio logo
ANVS
Annovis Bio
0.0$23.47-6.6%$163.05 millionN/A0.00Upcoming Earnings
Gap Down
ImmunoPrecise Antibodies logo
IPA
ImmunoPrecise Antibodies
0.0$7.72-1.8%$147.99 millionN/A0.00
EVAX
Evaxion Biotech A/S
1.7$6.63-0.8%$127.29 millionN/A0.00Upcoming Earnings
News Coverage
GANX
Gain Therapeutics
1.7$10.50-4.8%$118.98 millionN/A0.00Gap Up
LGVN
Longeveron
0.3$5.59-2.7%$105.97 millionN/A0.00
UPC
Universe Pharmaceuticals
0.0$3.19-0.0%$69.38 millionN/A0.00Quiet Period Expiration
VRDN
Viridian Therapeutics
1.7$17.53-1.0%$68.51 millionN/A0.00Earnings Announcement
News Coverage
This page was last updated on 5/8/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.